These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 34321343)

  • 1. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis.
    Shih ST; Farrar MA; Wiley V; Chambers G
    J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1296-1304. PubMed ID: 34321343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
    Dean R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Wiesner T; Malone DC; Bischof M; Toro W; Dabbous O
    J Mark Access Health Policy; 2021 Feb; 9(1):1889841. PubMed ID: 33708361
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy.
    Jalali A; Rothwell E; Botkin JR; Anderson RA; Butterfield RJ; Nelson RE
    J Pediatr; 2020 Dec; 227():274-280.e2. PubMed ID: 32659229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Onasemnogene Abeparvovec Compared With Nusinersen and Risdiplam in Patients With Spinal Muscular Atrophy Type 1 in Brazil: Custo-Efetividade do Onasemnogeno Abeparvoveque (AVXS-101) em Comparação ao Nusinersena e Risdiplam em Pacientes com Atrofia Muscular Espinhal Tipo 1 no Brasil.
    Fernandes BD; D'Athayde Rodrigues F; Cardoso Cirilo HN; Borges SS; Krug BC; Probst LF; Zimmermann I
    Value Health Reg Issues; 2024 Mar; 40():108-117. PubMed ID: 38181723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios.
    Broekhoff TF; Sweegers CCG; Krijkamp EM; Mantel-Teeuwisse AK; Leufkens HGM; Goettsch WG; Vreman RA
    Value Health; 2021 Jun; 24(6):759-769. PubMed ID: 34119073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments.
    Dangouloff T; Botty C; Beaudart C; Servais L; Hiligsmann M
    Orphanet J Rare Dis; 2021 Jan; 16(1):47. PubMed ID: 33485382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of gene-based therapies for patients with spinal muscular atrophy type I in Australia.
    Wang T; Scuffham P; Byrnes J; Downes M
    J Neurol; 2022 Dec; 269(12):6544-6554. PubMed ID: 35980467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1.
    Bischof M; Lorenzi M; Lee J; Druyts E; Balijepalli C; Dabbous O
    Curr Med Res Opin; 2021 Oct; 37(10):1719-1730. PubMed ID: 34236007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
    Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
    Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients.
    Malone DC; Dean R; Arjunji R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Dabbous O
    J Mark Access Health Policy; 2019; 7(1):1601484. PubMed ID: 31105909
    [No Abstract]   [Full Text] [Related]  

  • 11. Postnatal management of preterm infants with spinal muscular atrophy: experience from German newborn screening.
    Trollmann R; Johannsen J; Vill K; Köhler C; Hahn A; Illsinger S; Pechmann A; Hagen MV; Müller-Felber W
    Orphanet J Rare Dis; 2024 Sep; 19(1):353. PubMed ID: 39327607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
    Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
    Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go.
    Dangouloff T; Vrščaj E; Servais L; Osredkar D;
    Neuromuscul Disord; 2021 Jun; 31(6):574-582. PubMed ID: 33985857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US.
    Thokala P; Stevenson M; Kumar VM; Ren S; Ellis AG; Chapman RH
    Cost Eff Resour Alloc; 2020; 18():41. PubMed ID: 33041673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent 'value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective.
    Connock M; Andronis L; Auguste P; Dussart C; Armoiry X
    Expert Opin Biol Ther; 2020 Jul; 20(7):823-827. PubMed ID: 32434404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination molecular therapies for type 1 spinal muscular atrophy.
    Harada Y; Rao VK; Arya K; Kuntz NL; DiDonato CJ; Napchan-Pomerantz G; Agarwal A; Stefans V; Katsuno M; Veerapandiyan A
    Muscle Nerve; 2020 Oct; 62(4):550-554. PubMed ID: 32710634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England.
    Weidlich D; Servais L; Kausar I; Howells R; Bischof M
    Neurol Ther; 2023 Aug; 12(4):1205-1220. PubMed ID: 37222861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Technologies for the Treatment of Spinal Muscular Atrophy: A Systematic Review of Economic Studies.
    Motta-Santos A; Noronha K; Reis C; Freitas D; Carvalho L; Andrade M
    Value Health Reg Issues; 2024 Jul; 42():100985. PubMed ID: 38669792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec-xioi in a premature neonate with type 1 spinal muscular atrophy.
    Ferrante L; Melendez-Zaidi A; Lindsey W; Lotze T
    Muscle Nerve; 2022 Aug; 66(2):E8-E10. PubMed ID: 35616550
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of spinal muscular atrophy newborn screening based on real-world data in Belgium.
    Dangouloff T; Thokala P; Stevenson MD; Deconinck N; D'Amico A; Daron A; Delstanche S; Servais L; Hiligsmann M
    Neuromuscul Disord; 2024 Jan; 34():61-67. PubMed ID: 38150893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.